As of today, 26 TARPSWG centers confirmed to participate in the study, and 3 more centers are interested to join the study in next future.
Among interested centers there are 15 American institutions, 13 European institutions and 1 institution from Australia. Seven centers are already recruiting. Four centers obtained IRB approval and are ready to recruit. Five centers are waiting for IRB approval, while 11 are planning to submit to the IRB.
If estimates will be confirmed, the recruiting centers will be able to approximately enroll 350 new patient operated for primary retroperitoneal sarcoma per year.
Click here for RESAR study outline
Click here to see activated centers